- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04252144
Study of Dietary Patterns and Food Diversity in Russian GERD Patients
February 2, 2022 updated by: Vasily Isakov, Russian Academy of Medical Sciences
The aim of the study is to assess food diversity and dietary patterns in Russian GERD patients
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study of dietary patterns may provide complex vision of an association between consumption of specific foods, or groups of food products and manifestations of gastroesophageal reflux disease (symptoms: heartburn and acid regurgitation; endoscopic findings - oesophagitis).
Only limited data on this matter are published to the moment and they predominantly concerns outcomes of gastroesophageal reflux disease (oesophageal adenocarcinoma or Barrett's oesophagus).
Taking into the consideration that earlier studies found significant differences in consumption of nutrients in different world regions, new data on food patterns of dietary patterns in Russian GERD patients could partly fill in the gap of knowledge on this particular matter.
Study Type
Interventional
Enrollment (Anticipated)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Vasily Kropochev, MD
- Phone Number: +74997943572
- Email: followkropochev@ya.ru
Study Locations
-
-
-
Moscow, Russian Federation, 115446
- Recruiting
- Gastroenterology and Hepatology, FRC Nutrition and Biotechnology
-
Contact:
- Vasily Kropochev, MD
- Phone Number: +74997943572
- Email: followkropochev@ya.ru
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- willingness to participate (signed the informed consent form);
- willingness to follow all the required procedures;
Exclusion Criteria:
- Pregnant or breast-feeding females;
- Neoplasms, current or by the medical history (except local skin cancer successfully treated);
- History of chest or abdominal surgery, except appendectomy and cholecistectomy (in case when no consequences of these operations like adhesive disease of the abdominal cavity are present);
- Co-morbid conditions which can influence or mask the symptoms of GERD (including, but not limited to: ischaemic heart disease, severe pulmonary disease, severe depression or anxiety, etc);
- the use of concomitant medications that may influence on the symptoms or other manifestations of gastroesophageal reflux disease: NSAIDs, corticosteroids (except topic ones for no longer than 2 weeks), any medications directly influencing mood and function of central nervous system (antidepressants, anxiolytics, anti-anxiety agents, anticonvulsant etc) at the moment of enrolment and during a 2 half-life period of the certain drug;
- the use of medications that influence gastric secretion at the time of enrolment and during 2 week before it;
- any condition of the patient which makes the participation of the patient in the study unreasonable or put him at risk of the condition's exacerbation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NON_RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: GERD
Patients with verified gastroesophageal reflux disease
|
Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia.
Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.
Other Names:
|
OTHER: Contol
Mostly healthy subjects who have no symptoms and other manifestations of gastroesophageal reflux disease by complex examination
|
Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia.
Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
grains consumption diversity
Time Frame: a month
|
Mean number of different types of grains consumed in form of different foods or food products a month during 12-months period
|
a month
|
meat consumption diversity
Time Frame: a month
|
Mean number of different types of meat consumed in form of different foods or food products a month during 12-months period
|
a month
|
poultry consumption diversity
Time Frame: a month
|
Mean number of different types of poultry consumed in form of different foods or food products a month during 12-months period
|
a month
|
fish consumption diversity
Time Frame: a month
|
Mean number of different types of fish consumed in form of different foods or food products a month during 12-months period
|
a month
|
flour consumption diversity
Time Frame: a month
|
Mean number of different types of flours consumed in form of different foods or food products a month during 12-months period
|
a month
|
vegetables consumption diversity
Time Frame: a month
|
Mean number of different types of vegetables consumed as is or in the form of different foods or food products
|
a month
|
Fruits consumption diversity
Time Frame: a month
|
Mean number of different types of fruits consumed as is or in the form of different foods or food products
|
a month
|
Fats consumption diversity
Time Frame: a month
|
Mean number of different types of fats consumed in the form of different foods or food products a month by 12 month period
|
a month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GERD-associated dietary pattern
Time Frame: a year
|
complex of nutrients and/or foods (food products) which correlates with presence of GERD.
The correlation coefficients for each food item is range in the order of significance and direction of the relationship and in accordance to the amount of the product consumed, than is formed to the integral mean.
|
a year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Vasily Isakov, MD, PhD, Professor, AGAF, FRC Nutrition and Biotechnology
- Principal Investigator: Sergey Morozov, MD, PhD, FRC Nutrition and Biotechnology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 30, 2020
Primary Completion (ANTICIPATED)
September 30, 2023
Study Completion (ANTICIPATED)
December 31, 2023
Study Registration Dates
First Submitted
January 31, 2020
First Submitted That Met QC Criteria
January 31, 2020
First Posted (ACTUAL)
February 5, 2020
Study Record Updates
Last Update Posted (ACTUAL)
February 3, 2022
Last Update Submitted That Met QC Criteria
February 2, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-76-30014 GERD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Study data may be shared by request after study completion, except subjects' personal (identification) information
IPD Sharing Time Frame
After the study completion, available for 2 years
IPD Sharing Access Criteria
By request
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroesophageal Reflux
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
TakedaTerminatedGastroesophageal Reflux Disease | Non-erosive Reflux DiseaseSwitzerland, Netherlands
-
Klinikum Garmisch-PatenkirchenNot yet recruitingReflux, Gastroesophageal | Gastro-esophageal RefluxGermany
-
Mansoura UniversityWithdrawnGastroesophageal Reflux Disease
-
Cliniques universitaires Saint-Luc- Université...UnknownGastroesophageal Reflux DiseaseBelgium
-
King Chulalongkorn Memorial HospitalCompleted
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedGastroesophageal Reflux Disease (GERD) | RefluxUnited States, Canada
-
Vanderbilt University Medical CenterCompletedGastroesophageal Reflux Disease (GERD) | Non-erosive Reflux Disease (NERD)United States
Clinical Trials on Dietary assessment
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCancer SurvivorUnited States
-
PepsiCo Global R&DCompleted
-
King's College LondonZoe Global LimitedNot yet recruiting
-
Ohio State University Comprehensive Cancer CenterCompletedObesity | Overweight | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingWeight Loss | Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Cancer Fatigue | C-Reactive Protein MeasurementUnited States
-
City of Hope Medical CenterPatient-Centered Outcomes Research Institute; National Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Digestive System Carcinoma | Malignant Female Reproductive System Neoplasm | Genitourinary System CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Brander Beacons Cancer ResearchRecruitingCancer Survivor | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 and other conditionsUnited States
-
Harokopio UniversityEmbryogenesis Assisted Conception UnitCompleted
-
Kocaeli UniversityActive, not recruiting
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC... and other conditionsUnited States